Jefferies Financial Group Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP)
Jefferies Financial Group assumed coverage on shares of Rapport Therapeutics (NASDAQ:RAPP – Free Report) in a report released on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $35.00 price objective on the stock. Separately, Stifel Nicolaus started coverage on Rapport Therapeutics in a report on Tuesday. They set a buy rating and […]
More Stories
Chanson International (NASDAQ:CHSN) versus Nestlé (OTCMKTS:NSRGY) Critical Survey
Nestlé (OTCMKTS:NSRGY – Get Free Report) and Chanson International (NASDAQ:CHSN – Get Free Report) are both consumer staples companies, but...
Arctic Star Exploration (CVE:ADD) Trading Up 50% – Still a Buy?
Shares of Arctic Star Exploration Corp. (CVE:ADD – Get Free Report) shot up 50% during mid-day trading on Saturday ....
Head to Head Comparison: iTeos Therapeutics (NASDAQ:ITOS) & Invivyd (NASDAQ:IVVD)
Invivyd (NASDAQ:IVVD – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but...
Oracle Power (LON:ORCP) Trading Down 14.3% – Here’s Why
Oracle Power plc (LON:ORCP – Get Free Report)’s share price traded down 14.3% during mid-day trading on Saturday . The...
Protagenic Therapeutics, Inc. Enters into Amendment No. 1 to At Market Issuance Sales Agreement
On January 9, 2025, Protagenic Therapeutics, Inc. announced that it has entered into Amendment No. 1 to the At Market...
Weather, Power, and Water Issues Persist in Los Angeles’ Eaton Fire Area
By Beige Luciano-Adams LOS ANGELES—Residents eager to return home and survey vast damage wrought by the Eaton Canyon Fire in...